fluvastatinhttp://www.unboundmedicine.com/medline/ebm/research/fluvastatinUnbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.en-usUnbound Medicine, Inc.Local application of fluvastatin improves peri-implant bone quantity and mechanical properties: A rodent study.http://www.unboundmedicine.com/medline/ebm/record/19887121/full_citation/Local_application_of_fluvastatin_improves_peri_implant_bone_quantity_and_mechanical_properties:_A_rodent_study_Moriyama Y, Ayukawa Y, Ogino Y, et al. 
Local application of fluvastatin improves peri-implant bone quantity and mechanical properties: A rodent study. [JOURNAL ARTICLE]
Acta Biomater 2009 Oct 31.
Abstract | Full Citation | Find Related Articles In vitro interactions between primycin and different statins in their effects against some clinically important fungi.http://www.unboundmedicine.com/medline/ebm/record/19875509/full_citation/In_vitro_interactions_between_primycin_and_different_statins_in_their_effects_against_some_clinically_important_fungi_Nyilasi I, Kocsube S, Pesti M, et al. 
In vitro interactions between primycin and different statins in their effects against some clinically important fungi. [JOURNAL ARTICLE]
J Med Microbiol 2009 Oct 29.
Abstract | Full CitationInvestigation of the Rate-determining Process in the Hepatic Elimination of HMG-CoA Reductase Inhibitors in Rats and Humans.http://www.unboundmedicine.com/medline/ebm/record/19875501/full_citation/Investigation_of_the_Rate_determining_Process_in_the_Hepatic_Elimination_of_HMG_CoA_Reductase_Inhibitors_in_Rats_and_Humans_Watanabe T, Kusuhara H, Maeda K, et al. 
Investigation of the Rate-determining Process in the Hepatic Elimination of HMG-CoA Reductase Inhibitors in Rats and Humans. [JOURNAL ARTICLE]
Drug Metab Dispos 2009 Oct 29.
Abstract | Full CitationLiver X receptor agonist inhibits proliferation of ovarian carcinoma cells stimulated by oxidized low density lipoprotein.http://www.unboundmedicine.com/medline/ebm/record/19854496/full_citation/Liver_X_receptor_agonist_inhibits_proliferation_of_ovarian_carcinoma_cells_stimulated_by_oxidized_low_density_lipoprotein_Scoles DR, Xu X, Wang H, et al. 
Liver X receptor agonist inhibits proliferation of ovarian carcinoma cells stimulated by oxidized low density lipoprotein. [JOURNAL ARTICLE]
Gynecol Oncol 2009 Oct 23.
Abstract | Full CitationAsymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients.http://www.unboundmedicine.com/medline/ebm/record/19847152/full_citation/Asymmetrical_dimethylarginine_is_associated_with_renal_and_cardiovascular_outcomes_and_all_cause_mortality_in_renal_transplant_recipients_Abedini S, Meinitzer A, Holme I, et al. 
Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients. [JOURNAL ARTICLE]
Kidney Int 2009 Oct 21.
Abstract | Full Citation | Publisher Full Text | Find Related Articles Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin.http://www.unboundmedicine.com/medline/ebm/record/19842935/full_citation/Different_effects_of_the_ABCG2_c_421C>A_SNP_on_the_pharmacokinetics_of_fluvastatin_pravastatin_and_simvastatin_Keskitalo JE, Pasanen MK, Neuvonen PJ, et al. 
Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. [Journal Article]
Pharmacogenomics 2009 Oct; 10(10):1617-24.
Abstract | Full CitationRosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial.http://www.unboundmedicine.com/medline/ebm/record/19838098/full_citation/Rosuvastatin_versus_pravastatin_in_dyslipidemic_HIV_1_infected_patients_receiving_protease_inhibitors:_a_randomized_trial_Aslangul E, Assoumou L, Bittar R, et al. 
Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. [JOURNAL ARTICLE]
AIDS 2009 Oct 15.
Abstract | Full Citation | Publisher Full Text | Find Related Articles In-Vitro Release Kinetics and Stability of Anticardiovascular Drugs-Intercalated Layered Double Hydroxide Nanohybrids.http://www.unboundmedicine.com/medline/ebm/record/19831399/full_citation/In_Vitro_Release_Kinetics_and_Stability_of_Anticardiovascular_Drugs_Intercalated_Layered_Double_Hydroxide_Nanohybrids_Panda HS, Srivastava R, Bahadur D 
In-Vitro Release Kinetics and Stability of Anticardiovascular Drugs-Intercalated Layered Double Hydroxide Nanohybrids. [JOURNAL ARTICLE]
J Phys Chem B 2009 Oct 15.
Abstract | Full Citation | Find Related Articles Statins inhibit MMP release from human lung fibroblasts.http://www.unboundmedicine.com/medline/ebm/record/19797126/full_citation/Statins_inhibit_MMP_release_from_human_lung_fibroblasts_Kamio K, Liu XD, Sugiura H, et al. 
Statins inhibit MMP release from human lung fibroblasts. [JOURNAL ARTICLE]
Eur Respir J 2009 Sep 24.
Abstract | Full Citation | Publisher Full Text | Find Related Articles Novel synthetic inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity that inhibit tumor cell proliferation and are structurally unrelated to existing statins.http://www.unboundmedicine.com/medline/ebm/record/19787197/full_citation/Novel_synthetic_inhibitors_of_3_hydroxy_3_methylglutaryl_coenzyme_A__HMG_CoA__reductase_activity_that_inhibit_tumor_cell_proliferation_and_are_structurally_unrelated_to_existing_statins_Perchellet JP, Perchellet EM, Crow KR, et al. 
Novel synthetic inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity that inhibit tumor cell proliferation and are structurally unrelated to existing statins. [Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't]
Int J Mol Med 2009 Nov; 24(5):633-43.
Abstract | Full Citation